Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease

Davoud Mohtat, Rosemary Thomas, Zangfang Du, Yaa Boakye, Thomas Moulton, Catherine Driscoll, Robert Woroniecki

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
JournalPediatric Nephrology
Volume26
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Sickle Cell Anemia
Transforming Growth Factor beta
Transforming Growth Factors
Kidney
Hydroxyurea
Chronic Renal Insufficiency
Anemia
Hemoglobins
Fibrosis
Biomarkers
Wounds and Injuries
Lipocalin-2

Keywords

  • Biomarkers
  • Fibrosis progression
  • Sickle cell nephropathy

ASJC Scopus subject areas

  • Nephrology
  • Pediatrics, Perinatology, and Child Health

Cite this

Mohtat, D., Thomas, R., Du, Z., Boakye, Y., Moulton, T., Driscoll, C., & Woroniecki, R. (2011). Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease. Pediatric Nephrology, 26(2), 275-280. https://doi.org/10.1007/s00467-010-1677-9

Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease. / Mohtat, Davoud; Thomas, Rosemary; Du, Zangfang; Boakye, Yaa; Moulton, Thomas; Driscoll, Catherine; Woroniecki, Robert.

In: Pediatric Nephrology, Vol. 26, No. 2, 02.2011, p. 275-280.

Research output: Contribution to journalArticle

Mohtat, D, Thomas, R, Du, Z, Boakye, Y, Moulton, T, Driscoll, C & Woroniecki, R 2011, 'Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease', Pediatric Nephrology, vol. 26, no. 2, pp. 275-280. https://doi.org/10.1007/s00467-010-1677-9
Mohtat, Davoud ; Thomas, Rosemary ; Du, Zangfang ; Boakye, Yaa ; Moulton, Thomas ; Driscoll, Catherine ; Woroniecki, Robert. / Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease. In: Pediatric Nephrology. 2011 ; Vol. 26, No. 2. pp. 275-280.
@article{389a415be3954dc9843204e9bebaec7c,
title = "Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease",
abstract = "Renal dysfunction affects 5-18{\%} of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.",
keywords = "Biomarkers, Fibrosis progression, Sickle cell nephropathy",
author = "Davoud Mohtat and Rosemary Thomas and Zangfang Du and Yaa Boakye and Thomas Moulton and Catherine Driscoll and Robert Woroniecki",
year = "2011",
month = "2",
doi = "10.1007/s00467-010-1677-9",
language = "English (US)",
volume = "26",
pages = "275--280",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Urinary transforming growth factor beta-1 as a marker of renal dysfunction in sickle cell disease

AU - Mohtat, Davoud

AU - Thomas, Rosemary

AU - Du, Zangfang

AU - Boakye, Yaa

AU - Moulton, Thomas

AU - Driscoll, Catherine

AU - Woroniecki, Robert

PY - 2011/2

Y1 - 2011/2

N2 - Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.

AB - Renal dysfunction affects 5-18% of patients with sickle cell disease (SCD). To date, no studies have described urinary levels of transforming growth factor β-1 (TGF-β1), a marker of fibrosis, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute/chronic kidney disease, as biomarkers in identifying patients at risk of developing renal disease in SCD. We hypothesized that SCD subjects will have increased urinary excretion of TGF-β1 and NGAL compared with healthy controls (CTR). We examined 51 SCD subjects: 42 HbSS, 8 HbSC, and 1 HbSD. Sixteen out of 42 patients with HbSS were on hydroxyurea (HU). Urinary excretion of TGF-β1 was 26.4∈±∈1.5 pg/mgCr in SCD subjects vs 15. 0∈±∈2.4 pg/mgCr in CTR (p∈<∈0.00001). SCD patients with hemoglobin∈<∈9 g/dl had higher urinary TGF-β1 than patients with milder anemia (p∈=∈0.002). Urinary TGF-β1 trended lower in HbSS patients treated with HU (23.61∈±∈2.6 pg/mgCr), vs patients not on HU (27.69∈±∈1.8 pg/mgCr; p∈=∈0.055). There was no correlation between urinary TGF-β1 and microalbuminuria or estimated glomerular function. There was no difference in urinary NGAL in SCD patients vs CTR. We suggest that urinary TGF-β1 may serve as a marker of early renal injury in SCD.

KW - Biomarkers

KW - Fibrosis progression

KW - Sickle cell nephropathy

UR - http://www.scopus.com/inward/record.url?scp=78751591610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751591610&partnerID=8YFLogxK

U2 - 10.1007/s00467-010-1677-9

DO - 10.1007/s00467-010-1677-9

M3 - Article

VL - 26

SP - 275

EP - 280

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 2

ER -